Relay Therapeutics RLAY Stock
Relay Therapeutics Price Chart
Relay Therapeutics RLAY Financial and Trading Overview
Relay Therapeutics stock price | 7.5 USD |
Previous Close | 11.96 USD |
Open | 11.79 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 800 |
Day's Range | 11.72 - 12.96 USD |
52 Week Range | 9.67 - 33.06 USD |
Volume | 1.35M USD |
Avg. Volume | 1.64M USD |
Market Cap | 1.56B USD |
Beta (5Y Monthly) | 1.29903 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.79 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 27.05 USD |
RLAY Valuation Measures
Enterprise Value | 573.44M USD |
Trailing P/E | N/A |
Forward P/E | -3.6965318 |
PEG Ratio (5 yr expected) | 0.03 |
Price/Sales (ttm) | 1309.2848 |
Price/Book (mrq) | 1.7588009 |
Enterprise Value/Revenue | 482.691 |
Enterprise Value/EBITDA | -1.679 |
Trading Information
Relay Therapeutics Stock Price History
Beta (5Y Monthly) | 1.29903 |
52-Week Change | -20.65% |
S&P500 52-Week Change | 20.43% |
52 Week High | 33.06 USD |
52 Week Low | 9.67 USD |
50-Day Moving Average | 12.28 USD |
200-Day Moving Average | 17.62 USD |
RLAY Share Statistics
Avg. Volume (3 month) | 1.64M USD |
Avg. Daily Volume (10-Days) | 1.21M USD |
Shares Outstanding | 121.61M |
Float | 89.95M |
Short Ratio | 14.72 |
% Held by Insiders | 2.30% |
% Held by Institutions | 108.58% |
Shares Short | 21.16M |
Short % of Float | 22.91% |
Short % of Shares Outstanding | 17.39% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -29109.089% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -21.75% |
Return on Equity (ttm) | -37.40% |
Income Statement
Revenue (ttm) | 1.19M USD |
Revenue Per Share (ttm) | 0.01 USD |
Quarterly Revenue Growth (yoy) | -46.10% |
Gross Profit (ttm) | 1.38M USD |
EBITDA | -341464000 USD |
Net Income Avi to Common (ttm) | -322702016 USD |
Diluted EPS (ttm) | -2.95 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 937.8M USD |
Total Cash Per Share (mrq) | 7.71 USD |
Total Debt (mrq) | 56.75M USD |
Total Debt/Equity (mrq) | 6.42 USD |
Current Ratio (mrq) | 13.601 |
Book Value Per Share (mrq) | 7.272 |
Cash Flow Statement
Operating Cash Flow (ttm) | -247447008 USD |
Levered Free Cash Flow (ttm) | -132482000 USD |
Profile of Relay Therapeutics
Country | United States |
State | MA |
City | Cambridge |
Address | 399 Binney Street |
ZIP | 02139 |
Phone | 617 370 8837 |
Website | https://www.relaytx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 328 |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Q&A For Relay Therapeutics Stock
What is a current RLAY stock price?
Relay Therapeutics RLAY stock price today per share is 7.5 USD.
How to purchase Relay Therapeutics stock?
You can buy RLAY shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Relay Therapeutics?
The stock symbol or ticker of Relay Therapeutics is RLAY.
Which industry does the Relay Therapeutics company belong to?
The Relay Therapeutics industry is Biotechnology.
How many shares does Relay Therapeutics have in circulation?
The max supply of Relay Therapeutics shares is 131.18M.
What is Relay Therapeutics Price to Earnings Ratio (PE Ratio)?
Relay Therapeutics PE Ratio is now.
What was Relay Therapeutics earnings per share over the trailing 12 months (TTM)?
Relay Therapeutics EPS is -2.79 USD over the trailing 12 months.
Which sector does the Relay Therapeutics company belong to?
The Relay Therapeutics sector is Healthcare.
Relay Therapeutics RLAY included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16103.45 USD — |
+0.82
|
4.52B USD — | 16094.17 USD — | 16247.59 USD — | — - | 4.52B USD — |
NASDAQ Global Market Composite NQGM | 2185.85 USD — |
-0.31
|
— — | 2177.48 USD — | 2204.21 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 2078.81 USD — |
-0.4
|
— — | 2075.76 USD — | 2093.28 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2568.29 USD — |
+0.16
|
— — | 2566.7 USD — | 2581.47 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4337.34 USD — |
-0.65
|
— — | 4335.84 USD — | 4376.86 USD — | — - | — — |
NASDAQ HealthCare IXHC | 986.88 USD — |
-0.25
|
— — | 986.44 USD — | 994.67 USD — | — - | — — |
- {{ link.label }} {{link}}